Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction [1]

Blood

Volumn 96, Issue 12, 2000, Pages 4000-4001

  Roberts, Todd F ^a   Sprague, Kellie ^a   Schenkein, David ^a   Miller, Kenneth B ^a   Relias, Valerie ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CORTICOSTEROID; CYTARABINE; DEXAMETHASONE; IDARUBICIN; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; BRAIN INFARCTION; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DOSE RESPONSE; FEMALE; HUMAN; LETTER; LEUKOCYTOSIS; MORTALITY; PRIORITY JOURNAL; RELAPSE; THROMBOCYTE TRANSFUSION; TREATMENT FAILURE;

EID: 0034554742     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.12.4000.h8004000a_4000_4001     Document Type: Letter

References (4)

1. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
2. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
3. Leukocytosis and the 'Retinoic acid syndrome' during induction treatment of acute promyelocytic leukemia with arsenic trioxide
4. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PMN/RAR-α isoform, and CD13 expression in patients treated with all-trans retinoic acid